C9399 Unclassified Drugs — HCPCS Reimbursement

HCPCS Level II code C9399 denotes unclassified drugs or biologicals furnished in clinical settings where a specific HCPCS drug code is not available. Nationally, C9399 serves as a catch‑all billing pathway for novel, compounded, or otherwise unlisted drug and biologic products and can affect payment processing, documentation requirements, and prior authorization workflows across payers. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will gain a concise understanding of what C9399 represents, where it is typically used clinically (infusion centers, hospital outpatient departments, physician offices), and the administrative implications for unlisted drug billing. The publication summarizes common payer coverage considerations, typical billing modifiers and coding practices (overview only), and operational benchmarks such as claim adjudication pathways and documentation expectations. It also outlines the clinical context in which unclassified drug codes are used and highlights areas where payers commonly request additional clinical documentation or prior authorization. This briefing is designed to inform coding, billing, and revenue integrity teams, as well as clinical administrators, about the role and operational impacts of HCPCS Level II code C9399 in national drug and biologic billing.

Billing Code Overview

HCPCS Level II code C9399 represents unclassified drugs or biologicals not otherwise specified by a specific HCPCS Level II descriptor. The service type is drug or biological administration/supply and the typical site of service is outpatient infusion centers, hospital outpatient departments, physician offices, or other settings where drug or biologic products are furnished.

Data not available in the input.

Clinical Context

A patient with a rare or newly approved biologic therapy is scheduled to receive an outpatient infusion or injection billed under the unclassified HCPCS Level II code C9399 when no specific J‑code exists. Typical patients include those with refractory autoimmune diseases, rare hematologic disorders, or oncology indications for which the product is not yet assigned a permanent HCPCS code. The clinical workflow begins with a prescribing clinician (for example, a rheumatologist, hematologist/oncologist, or immunologist) documenting medical necessity and indication in the chart. The drug is obtained by the infusion center or pharmacy and verified by pharmacy staff for dosing and lot information. On the day of service the patient undergoes standard pre‑infusion assessment (vital signs, allergy check), informed consent when required, and administration by an infusion nurse or clinician. Medication preparation, administration time, and any monitoring or complication management (e.g., treatment of infusion reactions, additional observation time) are documented. Billing staff append C9399 with an appropriate modifier (for example, JW for discarded drug, JG is not listed so not used) and include drug name, strength, NDC, quantity, and route on the claim and in supporting documentation. Payer adjudication may require submitted manufacturer invoice, itemized drug receipt, and clinical notes demonstrating medical necessity. Typical sites of service are outpatient hospital infusion centers, physician office infusion suites, and specialty ambulatory infusion clinics. Patient scenario example: a 58‑year‑old with refractory autoimmune hemolytic anemia receives a novel biologic available through limited distribution; the hospital pharmacy prepares the dose, the patient is monitored for two hours post‑infusion for infusion‑related reactions, and the service is billed using C9399 with modifier JW for the portion discarded and modifier 52 if a reduced dose is administered due to tolerance concerns.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered to the patient	Use when part of a single‑use vial is discarded and you bill for the amount actually administered; append when required by payer to indicate discard.
`JZ`	No drug was administered from the vial	Use when no drug from the prepared vial was administered to the patient and documentation supports zero administration.
`52`	Reduced services	Use when a reduced dose or partial course of the drug is intentionally administered and documentation supports medical necessity for reduction.
`53`	Discontinued procedure	Use when the infusion or administration was started but discontinued for patient safety concerns (e.g., severe reaction).
`59`	Distinct procedural service	Use to indicate a separate and distinct drug administration event or when bundling edits need separation from another service on the same date.
`62`	Two surgeons	Use when two physicians of different specialties are simultaneously required to administer or supervise a complex biologic infusion procedure.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist billing as allowed by state law	Use when an advanced practice clinician performs or supervises the administration per payer rules.
`JW`	(See above)	(Avoid duplicate rows; JW is a primary discard modifier commonly required.)
`GZ`	Item or service expected to be denied as not reasonable/necessary	Use when the provider documents medical necessity but anticipates denial (no GA signature on file).
`QK`	Medical direction of two, three, or four concurrent anesthesia services by one physician	Use only if anesthesia services are required during the administration and the supervising physician directs multiple concurrent anesthetists.

Taxonomy Code	Specialty	Notes
207RH0000X	Hematology & Oncology	Hematologists/oncologists prescribe and oversee biologic therapies for cancer or hematologic disorders.
2080P0207X	Rheumatology	Rheumatologists commonly use biologics for autoimmune and inflammatory diseases requiring infusion services.
363L00000X	Infusion Therapy	Infusion nurses and clinics with this taxonomy manage and administer parenteral biologic agents.
207K00000X	Allergy & Immunology	Allergists/immunologists manage biologic therapies for immune‑mediated conditions and hypersensitivity evaluation.
363A00000X	Pharmacy	Clinical pharmacists manage procurement, compounding, dosing verification, and drug billing details.

Note: The selected modifier set focuses on discard, reduced or discontinued services, distinct service reporting, and common supervision or practitioner identifiers relevant to C9399 administration.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D59.1`	Other autoimmune hemolytic anemias	Biologics used for refractory autoimmune hemolytic anemia may be supplied as unclassified drugs billed with `C9399`.
`D66`	Hereditary factor VIII deficiency	Novel biologic or clotting factor therapies without permanent HCPCS codes may be billed as `C9399` in select cases.
`M32.10`	Systemic lupus erythematosus, organ or system involvement unspecified	Severe autoimmune disease requiring off‑label or newly approved biologics administered via infusion.
`M05.9`	Rheumatoid arthritis with rheumatoid factor, unspecified	Advanced biologic therapies for refractory rheumatoid arthritis sometimes require unclassified drug coding.
`D61.9`	Aplastic anemia, unspecified	For rare hematologic indications treated with experimental or limited‑distribution biologics billed as `C9399`.
`C80.1`	Malignant (primary) neoplasm, unspecified — often used for advanced malignancy needing novel agents	Oncology patients receiving novel biologic agents not yet assigned J‑codes may be billed using `C9399`.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, initial, for antineoplastic, chemotherapy, or other highly complex drug administration; up to 1 hour	Commonly billed for the initial infusion session when a biologic is administered intravenously alongside `C9399`.
`96366`	Intravenous infusion, each additional hour (List separately in addition to code for primary procedure)	Billed for extended infusion time beyond the first hour for prolonged biologic administrations.
`96367`	Intravenous infusion, each additional sequential infusion of a new drug	Used when multiple separate infusions are given in the same encounter with `C9399`.
`96413`	Chemotherapy administration, intravenous infusion technique; multiple drug infusions, up to 1 hour	Used when complex chemotherapy/biologic regimens require chemotherapy administration coding alongside the unclassified drug.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used for non‑intravenous biologic injections administered under `C9399` when coded as injection services.
`36415`	Collection of venous blood by venipuncture	Performed for pre‑administration labs or therapeutic drug monitoring related to biologic use and billed alongside `C9399`.

OpenPayer

Summary & Overview

HCPCS C9399: Unclassified Drugs or Biologicals